An Investigation of the impact of Faramir on the clinical symptoms in patients with COVID-19

An Investigation of the impact of Faramir containing Salvia officinalis leaf extract on the level of serum IL-6 in patients with COVID-19

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170315033086N7

Enrollment

128

Registered

2020-11-12

Start date

2020-11-21

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. Coronavirus infection, unspecified

Interventions

Intervention 1: Intervention group: Patients who receive natural product Faramir containing Salvia officinalis extract (750 mg oral caplet, 6 times a day, every 4 hours and for 8 days) along with stan

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Covid-19 infection confirmed by positive PCR-viral load test Some or all of the symptoms include fever, fatigue, muscle aches (headache), headache, cough, chest tightness, and shortness of breath Need to be hospitalized

Exclusion criteria

Exclusion criteria: Malignant tumors and other acute systemic diseases Co-infection with HIV and tuberculosis History of asthma, asthma-like attacks and respiratory problems Life-threatening comorbidity Use of any other herbal substance Homofusion and plasmapheresis Drug allergy Need for hospitalization in the intensive care unit (ICU) Pregnancy Lactation

Design outcomes

Primary

Measure	Time frame
Survival rate. Timepoint: 30 days after study commencement. Method of measurement: Deaths record.;Discharge duration. Timepoint: Hospitalization day and discharge day. Method of measurement: Record the number of hospitalization days.;Virus clearance. Timepoint: At the commencement of the investigation and 8 days after taking. Method of measurement: Polymerase chain reaction (PCR).;Serum Inflammatory Factors- Interleukin 6. Timepoint: At the beginning of the study and 8 days after the study commencement. Method of measurement: ELISA Method.	—

Measure

Time frame

Survival rate. Timepoint: 30 days after study commencement. Method of measurement: Deaths record.;Discharge duration. Timepoint: Hospitalization day and discharge day. Method of measurement: Record the number of hospitalization days.;Virus clearance. Timepoint: At the commencement of the investigation and 8 days after taking. Method of measurement: Polymerase chain reaction (PCR).;Serum Inflammatory Factors- Interleukin 6. Timepoint: At the beginning of the study and 8 days after the study commencement. Method of measurement: ELISA Method.

—

Secondary

Measure	Time frame
Serum Inflammatory Factors- c reactive protein (CRP). Timepoint: At the beginning of the study and 8 days after the study commencement. Method of measurement: ELISA Method.;Serum Inflammatory Factors- Erythrocyte sedimentation rate (ESR). Timepoint: At the beginning of the study and 8 days after the study commencement. Method of measurement: Western green method.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMinoosh Shabani

Shahid Beheshti University of Medical Sciences

minoosh.shabani@sbmu.ac.ir+98 21 5541 9005

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026